Roche reports failure of Prothena-partnered Parkinson's prospect in phase 2b but highlights positives

Back-to-back clinical failures have dealt further blows to efforts to treat Parkinson’s disease by targeting alpha-synuclein. Days after UCB reported the failure of its Novartis-partnered program, Roche has shared details of its own flop while clinging onto signs of clinical benefit that could still save the candidate.